Domestic heavy anti-cancer new drugs in the local landing, market pattern or change

On June 3, the State Drug Administration approved the listing of Zebutini capsulesThis is a new generation of BTK inhibitors developed by Baiji Shenzhou to treat adult set cell lymphoma (MCL) patients who have received at least one treatment in the past and adult chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one treatment in the pastit is learned that lymphoma is one of the top ten common malignant tumors in China, and it is also the malignant tumor with rapid incidence in China and around the worldZebtini is able to form complete, long-lasting precision suppression of BTK targetsRecently, at the 2020 American Society of Clinical Oncology (ASCO) online scientific meeting, Baiji Shenzhou announced the results of asPEN Phase 3 clinical trial follow-up for the treatment of Fahrenheit biibinibinibinibinibinib in patients with Fahrenheit cytoproteinemia (WM), new follow-up data show editinib compared to ibitinib to show higher safety and tolerance, while achieving higher complete and very good partial remission ratethe product was submitted for listing in China on 12 December 2018 and will be included in the priority review variety on 28 January 2019In November 2019, Zebutini accelerated the fda approval to go on the market, becoming the first new anti-cancer drug developed by Chinese enterprises and approved for listing in the United States, achieving a "zero breakthrough" in China's original research and new drugsThe product sold $720,000 in the U.Sin the first quarter of 2020, according to the datathe product was approved at the same time as two indications in China, less than seven months after it was approved for the U.Smarket, showing the strength of the rise of domestic innovative drugsdata show that BTK is a very prominent cutting edge in blood tumor research, there are currently a total of 4 BTK inhibitors approved for the market, in addition to Zebtini, there are ibitinib, Akatini and so on, ibitini was jointly developed by Johnson and Johnson and Pharmacyclics, the world's first approved BTK inhibitor, and then Pharmacyclics was acquired by AbbVie, with annual sales of Ibdini rising year by year since its listing, reaching $6.205 billion in 2018, ranking 11th on the 2018 global drug sales listZebutini is an FDA-approved BTK inhibitor that achieves a median 100% occupancy rate in peripheral blood cells, and a BTK inhibitor that can be taken once or twice a daythe BTK drug market will reach $17.8 billion by 2030 as penetration increases and indications expand, according to Frost and Sullivantarget ingress at the BTK drug market, domestic pharmaceutical companies are also in line, and a number of BTK target new drugs have entered clinical trials With zebtini coming to market first, or to change the btK inhibitor market landscape With only ibitinib approved in the country, Akatinib is still in clinical trials Zebutini is therefore expected to compete with Ibdini if he is approved it is understood that Ibtini spends $16,787 a month in the U.S., while Zebutini spends $12,935 a month in the U.S., 23 percent cheaper than Ibtini's in the U.S The industry expects that in the future Zebtini is also expected to take advantage of the price advantage in BTK inhibitors have a place data show that the Baiji Shenzhou research team in June 2012 officially launched the BTK development project, to the time of successful listing in China and the United States, after 8 years of long research and development process At present, Zebutini has launched nearly 25 clinical trials worldwide, covering more than 20 countries, with more than 500 international clinical experts participating in or presiding over Zebutini clinical trials, including more than 70 from China Globally, more than 1,700 patients received Zebutini treatment.